imidazole-1-carboxylic acid [5-(2-tert-butyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide | 790707-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: imidazole-1-carboxylic acid [5-(2-tert-butyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide
• 英文别名: imidazole-1-carboxylic acid [5-(2-tert-butyl-pyrimidin-4-yl)-4-methylthiazol-2-yl]-amide；N-(5-(2-tert-butylpyrimidin-4-yl)-4-methylthiazol-2-yl)-1H-imidazole-1-carboxamide；N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]imidazole-1-carboxamide
• CAS: 790707-13-0
• 化学式: C₁₆H₁₈N₆OS
• 分子量: 342.425
• InChiKey: IBOPEDSHCUSWAB-UHFFFAOYSA-N

物化性质

• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  imidazole-1-carboxylic acid [5-(2-tert-butyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide 、 L-脯氨酰胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-{5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}amide
  参考文献：
  名称：

  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

  摘要：

  Phosphatidylinositol-3-kinase alpha (PI3K alpha) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3K alpha, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.007
• 作为产物：
  描述：

  5-乙酰基-2-氨基-4-甲基噻唑 在 sodium hydroxide 作用下， 以 乙二醇甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 imidazole-1-carboxylic acid [5-(2-tert-butyl-pyrimidin-4-yl)-4-methyl-thiazol-2-yl]-amide
  参考文献：
  名称：

  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

  摘要：

  Phosphatidylinositol-3-kinase alpha (PI3K alpha) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3K alpha, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.007

文献信息

• Organic Compounds
  申请人：Caravatti Giorgio

  公开号：US20090163469A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：BRUCE Ian

  公开号：US20110105535A1

  公开（公告）日：2011-05-05

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3和R4的含义如说明书所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
  作者：Pascal Furet、Vito Guagnano、Robin A. Fairhurst、Patricia Imbach-Weese、Ian Bruce、Mark Knapp、Christine Fritsch、Francesca Blasco、Joachim Blanz、Reiner Aichholz、Jacques Hamon、Doriano Fabbro、Giorgio Caravatti

  DOI：10.1016/j.bmcl.2013.05.007

  日期：2013.7

  Phosphatidylinositol-3-kinase alpha (PI3K alpha) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3K alpha, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719. (C) 2013 Elsevier Ltd. All rights reserved.